

	I III AA IVENIEM I OI	1111					
Principal Investigator					IRB#		
HIPAA Reviewer's					π		
Name:					Date		
Name.					Date		
HIPAA Documents Review	wer Recommendation &	Comn	nents				
	_	_					
Ac	ccept	Rev	isions	Required		Not Accepted	
HIPAA Reviewer's Signa	iture						
eProtocol HIPAA Summa	rv Form						
Section		Yes	No	Comments			
Are all the elements of Ph	Il selected included for						
PHI that will be <b>USED</b> or <b>I</b>	DISCLOSED?						
1st box: Does the PHI tha	t will be <b>USED</b> match						
the HIPAA Authorization?							
2 <sup>nd</sup> box: Does the PHI tha	at will be <b>DISCLOSED</b>						
match the HIPAA Authoriz							
Items (a) & (b): Will someone with a clinical				If No, has a justification been provided?			
relationship contact potential participants?				Yes N		•	
Item(i): Are the entities in	odicated for the HIDAA						
form that will receive PHI	also listed for the HIPAA						
Authorization section: "You							
used or shared with the following section? This includes the students.							
and other companies	ly sponsor/fullding source						
Waiver of HIPAA Author	ization section						
Is a Waiver of Authorization							
To a Trairor of AdditionEdition	ni roquoticu.						
HIPAA Authorization & In	formed Consent Docum	ents					
Section		Yes	No	Comments			
HIPAA Authorization: H	as an option been						
provided regarding whether							
access to their medical re-							
HIPAA Information in Con	sent Documents or Addition	onal C	ommen	its:			
<del></del>							
Is a Waiver of HIPAA Auth	norization requested? $\lceil$	Ye	s. ao ta	next page	No.	STOP FORM IS COMPLETE	

## **Waiver of HIPAA Authorization**

Complete only if the Principal Investigator requests a Waiver of HIPAA Authorization

complete only if the initial investigator requests a waiver of thir AA Authorization						
The research could not practicably be conducted without the waiver or alteration.	True	False				
The research could not practicably be conducted without access to and use of the PHI.	True	False				
There is an adequate plan to protect health information identifiers from improper use and	True	False				
disclosure.						
There is an adequate plan to destroy identifiers at the earliest opportunity consistent with conduct of	f the researc	h (absent a				
health or research justification for retaining them or a legal requirement to do so).						
True						
False						
There is adequate justification to keep identifiers.						
There are adequate written assurances that the PHI will not be reused or disclosed to (shared	True	False				
with) any other person or entity, except as required by law, for authorized oversight of the						
research study, or for other research for which the use or disclosure of the PHI would be						
permitted under the Privacy Rule.						
Is a Waiver of HIPAA Authorization granted? Yes No Other:						
· — — — —						
Protocol-specific justification for a Waiver of HIPAA Authorization:						
Notes:						
A Waiver of Authorization is granted that allows for access to protected health information identified	as boing no	cossary for				
· · · · · · · · · · · · · · · · · · ·	as being ne	cessary ioi				
this study by the PI on the HIPAA Summary Form.						
It has been determined that a Waiven of Authorization (for this at only OD to severe for alimible nated	ial a autiais au	.4. : 46:				
It has been determined that a Waiver of Authorization (for this study OR to screen for eligible potent	ıaı participar	its in this				
study) satisfies the criteria of the Privacy Rule for the following reasons:						
- The research could not be practicably conducted without the Waiver of Authorization						
- The research could not be practicably conducted without access to and use of protected health information						
- There is an adequate plan to protect identifiers from improper use or disclosure.						
- There is an adequate plan to destroy identifiers at the earliest opportunity. Or There is adequate ju	stification fo	r the				
retention of identifiers.						
- The PI provided a signature on the Waiver Agreement which serves as written assurance that prof	ected health	information				
will not be reused or disclosed to any other person or entity, except as required by law, for authorize	ed oversight	of the				
research project, or for other research for which the use or disclosure of protected health information	n would be p	ermitted				
under the Privacy Rule.	•					
•						